In fact, there is evidence that ERβ expression sensitizes tumor cells to anti-androgen therapy, in AR-positive TNBC model [177], and to chemotherapy drugs doxorubicin and cisplatin in the presence of defective p53 [112]. This evidence concerns the gene TP53 and neoplasm.